Epizyme Inc. (NASDAQ:EPZM) rose 3.8% on Wednesday . The stock traded as high as $10.43 and last traded at $10.38, with a volume of 168,126 shares changing hands. The stock had previously closed at $10.00.

EPZM has been the subject of several analyst reports. Citigroup Inc. initiated coverage on Epizyme in a report on Tuesday, April 5th. They set a “buy” rating and a $17.00 target price for the company. JMP Securities restated a “buy” rating and set a $28.00 target price on shares of Epizyme in a report on Thursday, June 23rd. Mizuho restated a “buy” rating and set a $18.00 target price on shares of Epizyme in a report on Monday, June 20th. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Epizyme in a report on Monday, May 9th. Finally, Leerink Swann restated a “buy” rating on shares of Epizyme in a report on Tuesday, April 19th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. Epizyme has a consensus rating of “Buy” and a consensus target price of $23.11.

The stock’s market capitalization is $593.96 million. The company’s 50-day moving average price is $10.55 and its 200-day moving average price is $10.49.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. On average, equities analysts expect that Epizyme Inc. will post ($2.25) earnings per share for the current year.

In other news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $10.03, for a total transaction of $40,120.00. Following the transaction, the insider now owns 4,000 shares of the company’s stock, valued at $40,120. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Other hedge funds and institutional investors have added to or reduced their stakes in the company. Jennison Associates boosted its position in Epizyme by 0.6% in the third quarter. Jennison Associates now owns 253,668 shares of the biopharmaceutical company’s stock worth $3,262,000 after buying an additional 1,551 shares in the last quarter. California Public Employees Retirement System acquired a new position in Epizyme during the fourth quarter worth approximately $2,723,000. Finally, Jennison Associates LLC boosted its position in Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares in the last quarter.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.